Vertex Announces FDA Approval for Expanded Use of Casgevy for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
Vertex Pharmaceuticals announced FDA approval for expanded use of Casgevy (exagamglogene autotemcel) to treat sickle cell disease and transfusion-dependent beta thalassemia in patients ages 2 years and older. This regulatory approval expands the drug's previously authorized patient population.
Outcome Details
FDA approved expanded use of Casgevy for treatment of people ages 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia
Importance:8/10
Sentiment:
0.95
FDA approvallabel expansionrare diseasegene therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 1, 2026 11:07 PM